BIOLIFE SOLUTIONS INC — Director's Dealing 2023

Jan 10, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2023-01-03

Reporting Person: Phillips Geraint (SVP, Global Operations)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	38362	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Restricted Stock Award	$0.0000		Common Stock (9346)		Direct

Footnotes

F1: The amount represented in Column 2 of Table I includes 24,969 shares of the Company's common stock, 4,047 shares of restricted stock granted on August 9, 2021 pursuant to the BioLife Solutions 2013 Performance Incentive Plan, as amended (the "Plan"), which vests in equal quarterly installments, and 9,346 shares of restricted stock granted on February 24, 2022 pursuant to the Plan which vests in equal quarterly installments.

F2: The restricted stock was granted pursuant to the Plan on February 24, 2022. The restricted stock will vest as to between 0% and 200% of the reported number of shares in Column 3 of Table II based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date) and will vest on the date on which the registrant's board of directors determine the total shareholder return for the period.